Methacetin breath test in patients with cirrhosis

Utility of 13C-methacetin breath test in predicting long-term survival of patients with decompensated cirrhosis

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN11497545

Enrollment

123

Registered

2017-03-02

Start date

2009-01-01

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cirrhosis Digestive System Cirrhosis

Interventions

Consecutive patients with decompensated cirrhosis are studied at the Laboratory of Gastro-Hepatology of Centro Medico Nacional Siglo XXI. Diagnosis of decompensated cirrhosis based on history of prese

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age above 18 years 2. Diagnosis of decompensated cirrhosis based on history of present illness, clinical and biochemical findings combined with ultrasonographic results, plus liver biopsy when possible

Exclusion criteria

Exclusion criteria: Hepatocarcinoma

Design outcomes

Primary

Measure	Time frame
1. Survival is assessed through patient follow ups at least every 6 months for up to 3 years with analysis performed by the Kaplan-Meier method 2. The optimal cut-off point for predicting mortality to base line 13C-MetOx obtained by 13C-methacetin breath test within 3 years	—

Secondary

Measure	Time frame
The optimal cut-off point for predicting mortality to base line Child-Pugh (CP) and Meld Indexes within 3 years.	—

Countries

Mexico

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026